These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30573480)

  • 1. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study.
    Bourke JP; Watson G; Muntoni F; Spinty S; Roper H; Guglieri M; Speed C; McColl E; Chikermane A; Jayawant S; Adwani S; Willis T; Wilkinson J; Bryant A; Chadwick T; Wood R; Bushby K;
    BMJ Open; 2018 Dec; 8(12):e022572. PubMed ID: 30573480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
    Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
    Viollet L; Thrush PT; Flanigan KM; Mendell JR; Allen HD
    Am J Cardiol; 2012 Jul; 110(1):98-102. PubMed ID: 22463839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophy.
    Kipke J; Birnkrant DJ; Jin JB; Aneja A; Bahler RC
    Pediatr Pulmonol; 2021 Apr; 56(4):782-795. PubMed ID: 33621446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies.
    Mavrogeni SI; Markousis-Mavrogenis G; Papavasiliou A; Papadopoulos G; Kolovou G
    Methods Mol Biol; 2018; 1687():31-42. PubMed ID: 29067654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.
    Silva MC; Magalhães TA; Meira ZM; Rassi CH; Andrade AC; Gutierrez PS; Azevedo CF; Gurgel-Giannetti J; Vainzof M; Zatz M; Kalil-Filho R; Rochitte CE
    JAMA Cardiol; 2017 Feb; 2(2):190-199. PubMed ID: 27926769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left Ventricular Tonic Contraction as a Novel Biomarker of Cardiomyopathy in Duchenne Muscular Dystrophy.
    Su JA; Ramos-Platt L; Menteer J
    Pediatr Cardiol; 2016 Apr; 37(4):678-85. PubMed ID: 26714815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
    Ogata H; Ishikawa Y; Ishikawa Y; Minami R
    J Cardiol; 2009 Feb; 53(1):72-8. PubMed ID: 19167641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy.
    O'Brien L; Varadi R; Goldstein RS; Evans RA
    Chron Respir Dis; 2014 May; 11(2):103-10. PubMed ID: 24728656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial.
    Bourke JP; Watson G; Spinty S; Bryant A; Roper H; Chadwick T; Wood R; McColl E; Bushby K; Muntoni F; Guglieri M;
    Neurol Clin Pract; 2021 Oct; 11(5):e661-e668. PubMed ID: 34840880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Speckle-Tracking Echocardiography in Children With Duchenne Muscular Dystrophy: A Prospective Multicenter Controlled Cross-Sectional Study.
    Amedro P; Vincenti M; De La Villeon G; Lavastre K; Barrea C; Guillaumont S; Bredy C; Gamon L; Meli AC; Cazorla O; Fauconnier J; Meyer P; Rivier F; Adda J; Mura T; Lacampagne A
    J Am Soc Echocardiogr; 2019 Mar; 32(3):412-422. PubMed ID: 30679141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
    Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
    BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
    Raman SV; Hor KN; Mazur W; Halnon NJ; Kissel JT; He X; Tran T; Smart S; McCarthy B; Taylor MD; Jefferies JL; Rafael-Fortney JA; Lowe J; Roble SL; Cripe LH
    Lancet Neurol; 2015 Feb; 14(2):153-61. PubMed ID: 25554404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice.
    Blain A; Greally E; Laval SH; Blamire AM; MacGowan GA; Straub VW
    J Cardiovasc Transl Res; 2015 Apr; 8(3):198-207. PubMed ID: 25896492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry.
    Connuck DM; Sleeper LA; Colan SD; Cox GF; Towbin JA; Lowe AM; Wilkinson JD; Orav EJ; Cuniberti L; Salbert BA; Lipshultz SE;
    Am Heart J; 2008 Jun; 155(6):998-1005. PubMed ID: 18513510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cardiac medications on ventricular function in patients with Duchenne muscular dystrophy-related cardiomyopathy.
    Murphy AP; Johnson A; Straub V; Heads-Baister A; Lord S; Bourke JP
    Muscle Nerve; 2021 Aug; 64(2):163-171. PubMed ID: 34050938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.